Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs neostigmine for neuromuscular recovery and pulmonary complications after TURBT in elderly patients
ChiCTR2500112148Phase 4Not yet recruiting
- Sponsor
- Anqing Municipal Hospital
- Start
- Nov 2025
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Sugammadex in bladder cancer (2 arms), sponsored by Anqing Municipal Hospital. Primary endpoint: Postoperative pulmonary complication rate. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
Sugammadex
03
Conditions
bladder cancer
Beyond the preview
Go deeper on ChiCTR2500112148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112148.